Skip to Main Content

Author Details

Franklin W Huang
Institute for Human Genetics, University of California san francisco
1998
72
27
PMIDPaper TitleJournal TitlePublished Year
36658153Racial and ethnic disparities in a real-world precision oncology data registry.NPJ Precis Oncol2023
37565547Racial disparity in the genomics of precision oncology of prostate cancer.Cancer Rep (Hoboken)2023
37550827Club-like cells in proliferative inflammatory atrophy of the prostate.J Pathol2023
37145128Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.Cancer Res2023
37248397Understanding inequities in precision oncology diagnostics.Nat Cancer2023
37305584<i>TFG::ALK</i> fusion in ALK positive large B-cell lymphoma: a case report and review of literature.Front Oncol2023
36928719Cancer Demographics and Time-to-Care in Belize.Oncologist2023
36598071Transcriptomic profiling and genomic rearrangement landscape of Nigerian prostate cancer.Prostate2023
36658153Racial and ethnic disparities in a real-world precision oncology data registry.NPJ Precis Oncol2023
37550827Club-like cells in proliferative inflammatory atrophy of the prostate.J Pathol2023
37565547Racial disparity in the genomics of precision oncology of prostate cancer.Cancer Rep (Hoboken)2023
37248397Understanding inequities in precision oncology diagnostics.Nat Cancer2023
37145128Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.Cancer Res2023
37305584<i>TFG::ALK</i> fusion in ALK positive large B-cell lymphoma: a case report and review of literature.Front Oncol2023
36598071Transcriptomic profiling and genomic rearrangement landscape of Nigerian prostate cancer.Prostate2023
36928719Cancer Demographics and Time-to-Care in Belize.Oncologist2023
35261195COVID-19 outcomes in patients with cancer: Findings from the University of California health system database.Cancer Med2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
35657341The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.JNCI Cancer Spectr2022
36008377Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids.Nat Commun2022
36383412The <i>CIC-ERF</i> co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression.Elife2022
36511483Defining cellular population dynamics at single-cell resolution during prostate cancer progression.Elife2022
35261195COVID-19 outcomes in patients with cancer: Findings from the University of California health system database.Cancer Med2022
35111674Mutations in <i>JAK/STAT</i> and <i>NOTCH1</i> Genes Are Enriched in Post-Transplant Lymphoproliferative Disorders.Front Oncol2022
35084050Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.Prostate2022
35657341The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.JNCI Cancer Spectr2022
36511483Defining cellular population dynamics at single-cell resolution during prostate cancer progression.Elife2022
36383412The <i>CIC-ERF</i> co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression.Elife2022
36008377Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids.Nat Commun2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
35111674Mutations in <i>JAK/STAT</i> and <i>NOTCH1</i> Genes Are Enriched in Post-Transplant Lymphoproliferative Disorders.Front Oncol2022
35084050Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.Prostate2022
33153814Monitoring Prostate Cancer Incidence Trends: Value of Multiple Imputation and Delay Adjustment to Discern Disparities in Stage-specific Trends.Eur Urol2021
33539588Global Precision Oncology: A Call to Action on Expanding Access to Targeted Cancer Therapies.Oncologist2021
34063511A Rare Variant in <i>ERF</i> (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree.Cancers (Basel)2021
33571636Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry.Ann Oncol2021
34266915How Cancer Risk SNPs May Contribute to Prostate Cancer Disparities.Cancer Res2021
33835826Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry.JCO Glob Oncol2021
33980590<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor.J Immunother Cancer2021
33926541Evaluating the transcriptional fidelity of cancer models.Genome Med2021
33153814Monitoring Prostate Cancer Incidence Trends: Value of Multiple Imputation and Delay Adjustment to Discern Disparities in Stage-specific Trends.Eur Urol2021
34860566Implementing Patient-Directed Cancer Education Materials Across Nigeria.JCO Glob Oncol2021
34551377Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE).Cancer Genet2021
34486523Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines.Elife2021
34485840IGFBP-3 and TGF-β inhibit growth in epithelial cells by stimulating type V TGF-β receptor (TβR-V)-mediated tumor suppressor signaling.FASEB Bioadv2021
34994651Tumor Mutations Across Racial Groups in a Real-World Data Registry.JCO Precis Oncol2021
33571636Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry.Ann Oncol2021
33539588Global Precision Oncology: A Call to Action on Expanding Access to Targeted Cancer Therapies.Oncologist2021
33926541Evaluating the transcriptional fidelity of cancer models.Genome Med2021
33835826Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry.JCO Glob Oncol2021
  • 1 - 50 of 144

Recommended Authors

Rohan Bareja
Case Western Reserve University
Career Start Year 2017
Number of shared co-authors 36
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 26
Lina Gao
Oregon National Primate Research Center
Career Start Year 2010
Number of shared co-authors 9
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 25
John R Prensner
University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 27
Mark M Pomerantz
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 43
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 17
Svitlana Tyekucheva
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 23
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 15
Jamie K Teer
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 2005
Number of shared co-authors 4
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 13
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 20
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 22
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 6
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 77
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 9
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 2002
Number of shared co-authors 57
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 1
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 17
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 4
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 48
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 21
Hugues Sicotte
Mayo Clinic
Career Start Year 1999
Number of shared co-authors 6
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 52
Kathleen E Houlahan
University of California los angeles
Career Start Year 1991
Number of shared co-authors 17
Suzanne Carreira
The Institute of Cancer Research
Career Start Year 1990
Number of shared co-authors 39
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 20
Javed Siddiqui
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 1988
Number of shared co-authors 47
Katherine L Nathanson
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Career Start Year 1986
Number of shared co-authors 30
David M Berman
Queen's University
Career Start Year 1982
Number of shared co-authors 15

Collaborators

Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 11
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 8
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Brandon A Mahal
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
Co-authored papers 5
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 5
Gregory V Kryukov
Co-authored papers 5
Mahmoud Ghandi
Co-authored papers 5
Eric J Small
University of California san francisco
Co-authored papers 4
Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 4
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 4
Mark A Rubin
University of Bern
Co-authored papers 4
Stacey Gabriel
Broad Institute of MIT and Harvard
Co-authored papers 4
Pablo Tamayo
University of California San Diego
Co-authored papers 3
Mara Rosenberg
Broad Institute of MIT and Harvard
Co-authored papers 3
Stephanie A Wankowicz
University of California San Francisco
Co-authored papers 3
Ami S Bhatt
Stanford University
Co-authored papers 3
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 3
Lorelei A Mucci
Co-authored papers 3
Ilsa Coleman
Fred Hutchinson Cancer Center
Co-authored papers 3
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Michael S Lawrence
Co-authored papers 3
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 3
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Francesca Demichelis
University of Trento
Co-authored papers 3
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 3
Timothy R Rebbeck
Center for Cancer Equity and Engagement, Dana-Farber/Harvard Cancer Center
Co-authored papers 3
Jianjiong Gao
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
James C Costello
University of Colorado Anschutz Medical Campus
Co-authored papers 3
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 3
Matthew Meyerson
Broad Institute
Co-authored papers 3
Release 1.2